SCHEMBL3472281

SCHEMBL3472281

ON=C1CCCCCCCC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 1.00
CASP1 P29466 1/20 1.00
CHRNA7 P36544 1/20 0.40
ESR2 Q92731 2/20 0.39
KMT2A Q03164 2/20 0.33
MEN1 O00255 1/20 0.33
LMNA P02545 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
ALDH1A1 P00352 4/20 0.32
TRIM24 O15164 1/20 0.32
TRIM33 Q9UPN9 1/20 0.32
KDM4E B2RXH2 4/20 0.31
RAB9A P51151 1/20 0.31
HPGD P15428 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
CYP2D6 P10635 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1025357 1.00 TSHR (1.00) TSHRCASP1CHRNA7ESR2KMT2A
Cyclohexanone Oxime SCHEMBL15106892 1.00 TSHR (1.00) TSHRCASP1CHRNA7ESR2KMT2A
SCHEMBL3472303 1.00 TSHR (1.00) TSHRCASP1CHRNA7ESR2KMT2A
SCHEMBL3474721 1.00 TSHR (1.00) TSHRCASP1CHRNA7ESR2KMT2A
SCHEMBL3190316 1.00 TSHR (1.00) TSHRCASP1CHRNA7ESR2KMT2A
SCHEMBL1026335 1.00 TSHR (1.00) TSHRCASP1CHRNA7ESR2KMT2A
Cyclohexanone Oxime SCHEMBL37995 1.00
Cyclohexanone Oxime SCHEMBL11884936 1.00 TSHR (1.00) TSHRCASP1CHRNA7ESR2KMT2A
SCHEMBL1025656 1.00 TSHR (1.00) TSHRCASP1CHRNA7ESR2KMT2A
SCHEMBL1025081 1.00 TSHR (1.00) TSHRCASP1CHRNA7ESR2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025088970-A1 ELECTRODE MIXTURE, ACTIVE MATERIAL MIXTURE, BINDER SOLUTION, PRODUCTION METHOD FOR ELECTRODE MIXTURE, PRODUCTION METHOD FOR ELECTRODE, ELECTRODE, AND SECONDARY BATTERY 株式会社クレハ 2025-05-01 WO disclosed
US-11963527-B2 Compounds, compositions, and methods for altering insect and organism behavior BASF CORPORATION (US) 2024-04-23 US disclosed
US-20230335741-A1 BINDER, ELECTRODE MIXTURE, ELECTRODE, AND NON-AQUEOUS ELECTROLYTE SECONDARY BATTERY KUREHA CORPORATION (JP) 2023-10-19 US disclosed
EP-4206273-A1 BINDER, ELECTRODE MIXTURE, ELECTRODE, AND NONAQUEOUS ELECTROLYTE SECONDARY BATTERY Kureha Corporation (JP) 2023-07-05 EP disclosed
WO-2023054702-A1 ALDEHYDE COMPOUND PRODUCTION METHOD AND DIHYDROISOXAZOLE COMPOUND PRODUCTION METHOD クミアイ化学工業株式会社 2023-04-06 WO disclosed
WO-2022110930-A1 METHOD FOR AMMOXIMATION OF MACROCYCLOALKANONE 中国天辰工程有限公司 2022-06-02 WO disclosed
EP-2241552-B1 PRODUCTION METHOD AND BECKMANN REARRANGEMENT CATALYST FOR PRODUCING A CYCLIC LACTAM COMPOUND UNIV NAGOYA NAT UNIV CORP (JP) 2018-11-14 EP disclosed
US-9411226-B2 Chemically amplified resist composition and patterning process SHIN-ETSU CHEMICAL CO., LTD. (JP) 2016-08-09 US disclosed
US-9411226-B2 Chemically amplified resist composition and patterning process SHIN-ETSU CHEMICAL CO., LTD. (JP) 2016-08-09 US disclosed
EP-2241552-A1 PRODUCTION METHOD AND BECKMANN REARRANGEMENT CATALYST FOR PRODUCING A CYCLIC LACTAM COMPOUND National University Corporation Nagoya University (JP) 2010-10-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11963527-B2 Compounds, compositions, and methods for altering insect and organism behavior ACHE, DDT, MGLL TSHR 2908/4885CASP1 1427/4885CHRNA7 3301/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.